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Abstract 22 
The ability to rapidly detect circulating small RNAs, in particular microRNAs (miRNAs), would 23 
further increase their already established potential as biomarkers in a range of conditions. One rate-24 
limiting factor is the time taken to perform quantitative real time PCR amplification. We therefore 25 
evaluated the ability of a novel thermal cycler to perform this step in less than 10 minutes. 26 
Quantitative PCR was performed on an xxpress® thermal cycler (BJS Biotechnologies, Perivale, 27 
UK), which employs a resistive heating system and forced air cooling to achieve thermal ramp rates 28 
of 10 °C/s, and a conventional peltier-controlled LightCycler 480 system (Roche, Basel, Switzerland) 29 
ramping at 4.8 °C/s. The threshold cycle (Ct) for detection of 18S rDNA from a standard genomic 30 
DNA sample was significantly more variable across the block (F-test, p=2.4x10-25) for the xxpress 31 
(20.01±0.47SD) than the LightCycler (19.87±0.04SD). RNA was extracted from human plasma, 32 
reverse transcribed and a panel of miRNAs amplified and detected using SYBR green (Kapa 33 
Biosystems, Wilmington, Ma, USA). The sensitivity of both systems was broadly comparable and 34 
both detected a panel of miRNAs reliably and indicated similar relative abundances. The xxpress 35 
thermal cycler facilitates rapid qPCR detection of small RNAs and brings point-of care diagnostics 36 
based upon circulating miRNAs a step closer to reality.  37 
 38 
Method summary 39 
We describe a quantitative PCR platform which enables faster ramping between temperatures than 40 
conventional peltier-based systems, thereby reducing the time required to complete a PCR reaction. 41 
This is particularly important for the development of clinical biomarkers for acute conditions and the 42 
feasibility of detecting miRNAs in plasma is demonstrated. 43 
 44 
 45 
 46 
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Introduction 47 
PCR is ubiquitous throughout the life and medical sciences and a reduction in the time required to 48 
complete a PCR reaction would therefore be of immense benefit. Whilst the choice of fast enzyme is 49 
important for the optimization of fast PCR-based systems(1), (2),  the speed at which the temperature 50 
of the sample can be altered during thermal cycling is the primary rate-limiting factor (3). Using 51 
prototype systems many investigators have demonstrated that rapid thermal cycling is possible (4), 52 
(5), and under extreme conditions can be completed in less than one minute (6)! The predominant 53 
format of existing thermal cyclers comprises a 96 or 384 well block, the temperature of which is 54 
controlled by a peltier-based system limited to ramp rates of approximately 4 °C/s. Several 55 
quantitative PCR systems which employ rapid thermal cycling are available commercially, but these 56 
are based on glass capillaries (LightCycler, Roche) (7) or plastic tubes placed in a centrifuge (Rotor-57 
gene, Qiagen, Crawley, UK). An alternative rapid plate-based approach, which can be more easily 58 
integrated into existing workflows, has now been developed. The xxpress® thermal cycler (BJS 59 
Biotechnologies) employs resistive heating and forced air cooling to enable ramp rates of up to 10 60 
°C/s. 61 
One of the main applications of PCR is for the quantitation of RNA targets. Following reverse 62 
transcription into cDNA, amplification of targets is detected by incorporation of a double-stranded 63 
DNA binding fluorescent dye (principally SYBR green) or use of a sequence-specific probe-based 64 
system e.g. Taqman. This quantitative reverse transcription PCR (RT-qPCR) approach can be 65 
modified to measure small RNAs, specifically miRNAs. Following the discovery that miRNAs exist 66 
in a stable form within blood (8)(9)), their potential as biomarkers was soon realised. MiRNA 67 
expression patterns characteristic of cancer, cardiovascular disease, diabetes, Alzheimer's and many 68 
other conditions have now been reported (10)(11), (12, 12). Typically global miRNA profiles are 69 
initially assessed in a discovery cohort using microarrays or deep sequencing and selected informative 70 
miRNAs are subsequently measured in a larger population. The method of choice for measuring a 71 
defined, diagnostic panel of miRNAs is RT-qPCR.  72 
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To perform RT-qPCR, RNA must be extracted from plasma or serum, reverse transcribed and target 73 
miRNAs amplified in individual PCR reactions. This process takes several hours and is sufficient for 74 
the current applications of circulating miRNA biomarkers for which results may be reported within 75 
days or weeks. However, a more rapid assay would facilitate point of care diagnostics and expand 76 
potential uses. For example, changes in miRNAs have been associated with cardiac disease (10)), and 77 
the ability to measure them in plasma quickly might provide an earlier biomarker for diagnosis of 78 
myocardial infarction and ensure more timely therapeutic intervention (13). We therefore assessed the 79 
ability of the xxpress system to quantify miRNAs in plasma using high speed cycling in comparison 80 
with an existing qPCR system (LightCycler480, Roche).   81 
It was possible to amplify RNAs from plasma cDNA in less than 10 minutes using the xxpress 82 
system, compared with ~40 minutes with the LightCycler. However, although the performance of 83 
both systems was broadly comparable, variability across the plate and between replicate samples was 84 
greater in the xxpress. 85 
 86 
Materials and Methods  87 
Oligonucleotide synthesis 88 
All oligonucleotides (Integrated DNA Technologies,  Leuven, Belgium) were reconstituted as 100 µM 89 
stocks; DNA in TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0), RNA in nuclease free water, and 90 
stored at -80 °C. Sequences of the RNA miRNA mimic, Reverse transcription oligo, 18S and miRNA 91 
primers are shown in Table 1.  92 
 93 
qPCR instruments 94 
The xxpress system (Figure 1) employs resistive heating and forced air cooling to facilitate rapid 95 
changes in temperature. PCR reactions are performed within proprietary ‘xxplates’ which comprise a 96 
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metal base fused with plastic wells, meaning that the sample is only 10 µm from the heat source 97 
(Figure 1A). To enable thermal uniformity across all the samples to within ±0.3 °C during holds at a 98 
static temperature or within ±0.8 °C during fast ramping (10 °C/s), the xxpress uses an array of 99 
infrared sensors to determine the temperature of the test samples and a control algorithm adjusts the 100 
heating patterns at a rate of 100 times per second.  The xxplates to be analysed using the xxpress 101 
system were prepared as follows. Plates were sealed using xxpress compatible polarised sealing strips 102 
heated at 170 oC for 1.5 s using the heat sealer provided (Figure 1B). They were then centrifuged at 103 
1000 rpm for 1 minute in dedicated holders in the centrifuge provided before loading into the xxpress 104 
cycling unit (Figure 1B). The LightCycler 480 system with a 384 well block installed has a thermal 105 
uniformity of ±0.4 °C within 60 s of target attainment (72 °C). PCR plates (Roche) to be analysed 106 
were prepared following the manufacturer's instructions (LightCycler 480 user manual). In brief, 107 
plates were sealed using the manufacturer's sealing strips, ensuring all wells were securely covered, 108 
followed by centrifugation at 1200 rpm for 2 minutes. Plates were then loaded into the LightCycler.  109 
 110 
PCR conditions and data analysis 111 
All PCR reactions were performed for 40 cycles with SYBR Fast qPCR Mastermix (final 112 
concentration 1X, Kapa Biosystems, 1 µl DNA or cDNA template, 5 µM forward and reverse 113 
primers) in a final volume of 5 µl. The cycling conditions used for amplification of 18S rDNA are 114 
shown in Table 2 and employed the same ramp rate on both machines (4.8 °C/s). 18S rDNA 115 
amplification used 1 µl of genomic DNA as template (2.5 ng/µl) either neat, or serially diluted in PCR 116 
grade water. The same conditions were used for detection of miRNAs, but with a reduced 117 
annealing/extension temperature of 55 °C and with ramp rates increased to 10 °C/s on the xxpress. 118 
Raw fluorescence data were analysed by baseline normalisation and Ct values were called in 119 
accordance with the data analysis software provided on each instrument (threshold set using the 120 
second derivative maximum algorithm on the LightCycler and manually on the xxpress).  121 
 122 
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RNA templates 123 
An RNA oligonucleotide with the sequence of miR-21 and a polyA tail (miRNA mimic) (Table 1) 124 
was reverse transcribed using 5 pmol of oligodT-RACE primer; the template was denatured at 50 °C 125 
for 5 minutes, then cooled to 4 °C for addition of SuperScript III (Life Technologies, Paisley, UK) 126 
followed by incubation at 40 °C  for 60 minutes. Total RNA including small RNAs was extracted 127 
from 200 µl of human plasma using a miRNeasy Serum/plasma kit according to the manufacturer’s 128 
protocol (Qiagen, Crawley, UK) and polyadenylated for 1 hour at 37 °C in a 25 µl reaction containing 129 
2 U poly(A) polymerase, 2.5mM MgCl2 and 1mM ATP (Ambion, Life Technologies). A 5 µl volume 130 
of polyadenylated RNA was then incubated at 65 °C for 5 minutes with 0.5 µg oligo(dT)-RACE 131 
primer and 1µl 10 mM dNTPs in a reaction volume of 8 µl. Following addition of 200 U SuperScript 132 
III, 1 U RNaseOut, 1 µl 0.1 M DTT and 4 µl 5X RT buffer, the reaction was incubated at 50 °C for 1 133 
hour followed by 70 °C for 15 minutes. 134 
 135 
Ethics 136 
This study was conducted according to the guidelines laid down in the Declaration of Helsinki and all 137 
procedures involving human participants/patients were approved by the Research Ethics Committee 138 
of the School of Medicine and Dentistry, Queen’s University Belfast (Ref:11/05v3). Written informed 139 
consent was obtained from all participants 140 
 141 
Results and Discussion 142 
To assess consistency across the plate, a single mastermix for amplification of a 155 bp amplicon 143 
from 18S rDNA was aliquoted into 48 wells distributed evenly across each type of plate (Suppl. 144 
Figure. 1). Amplification was performed using the same cycling conditions on both systems (Table 2). 145 
The mean Ct values were very similar from the xxpress (20.01±0.47SD) and the LightCycler 146 
(19.87±0.04SD), although the LightCycler was significantly lower (t-test, p = 0.035).  However the 147 
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xxpress exhibited significantly greater variability than the LightCycler, which generated extremely 148 
consistent Ct values (F-test, p=2.4x10-25) (Figure 2). Although the performance of the xxpress was 149 
less robust, it could still be used in situations requiring rapid detection of large variations in 150 
expression between samples (with the inclusion of appropriate replicates). The spread in Ct values on 151 
the xxpress was in part linked to the position of the sample on the xxplate, with adjacent wells tending 152 
to vary from the mean Ct value in the same direction. The greater variation observed with the xxpress 153 
may not be due to poorer temperature control across the plate, but could be related to the optical 154 
system, which is amenable to improvement  in subsequent versions. To compare the sensitivity of the 155 
two platforms, highly abundant 18S rDNA was amplified from a dilution series of genomic DNA. The 156 
mean Ct values at each template concentration were not significantly different between platforms (t-157 
test, p>0.05). In both cases the Ct values were highly correlated with template concentration 158 
(LightCycler, R² = 0.9547; xxpress, R² = 0.9878), although again there was a significantly greater 159 
variation in Ct values for replicates in the xxpress at several concentrations (Figure 3A).  160 
The method described by Shi and Chiang (14)), was then used to detect miRNAs. Total RNA, 161 
including miRNAs, is polyadenylated and then reverse-transcribed with a poly(T) adapter into 162 
cDNAs. These are subsequently amplified using a miRNA-specific forward primer and a sequence 163 
complementary to the poly(T) adapter as the reverse primer.  Initially we tested the ability of each 164 
platform to detect a miRNA mimic synthesised with a polyA tail already incorporated (thereby 165 
removing any variability associated with the polyadenylation reaction). The limit of detection, as 166 
estimated from the linear portion of the standard curve, was approximately 1x106 RNA template 167 
molecules for both systems (Figure 3B). Given the high concentrations of specific template miRNA 168 
used in this assay, a better signal may be obtained using cell-derived RNA as template (15)). 169 
Our ultimate aim is the rapid detection of miRNAs from blood as biomarkers of cancer and other 170 
diseases. As a step towards this we measured the expression of several miRNAs in RNA extracted 171 
from three human plasma samples; miR-21, an ‘oncomir’ which plays a role in many types of cancer 172 
(16), (17),(18)and heart disease (19)) and has been reported to be elevated in blood from cancer 173 
patients (20), (21), miR-22, which has is also differentially expressed in various types of cancer (22)), 174 
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miR-126, which is involved in regulation of angiogenesis (23)) and miR-486, which is down-175 
regulated in lung cancer and proposed as a biomarker for detection of lung cancer in plasma samples 176 
((24), (25)). The results of quantification of these four miRNAs following forty cycles of PCR, 177 
completed in less than 10 minutes with the xxpress compared to 40 minutes using the LightCycler, are 178 
presented in Figure 4. The relative abundances of the miRNAs detected by both systems were similar, 179 
albeit with greater variation between technical replicates on the xxpress. MiR-21 was the most 180 
abundant (lowest Ct) and miR-22 the least abundant (highest Ct) miRNA for all samples on both 181 
platforms.  Significant differences between platforms in Ct values were observed for many miRNAs 182 
amplified from the same sample (e.g. miR-126 in plasma sample 2, p <0.001). This is likely due to the 183 
combined effects of differences in the sample temperatures achieved during cycling, the detection 184 
systems and performance of the individual assays under different conditions. Another class of small 185 
RNA, a Y RNA fragment (hY4-3p) recently shown to be present in plasma (26), (27, 28) was detected 186 
consistently by both platforms (∆Ct between the two platforms across three plasma samples was  2.3 187 
±0.3SD) and could potentially provide a stable reference gene.  188 
Faster PCR can be achieved by reducing hold times and although this can reduce sensitivity and 189 
increase variability (29)) , enzymes are now available from a range of manufacturers which perform 190 
well in fast PCR. All data reported were generated with SYBR fast qPCR Mastermix (Kapa 191 
Biosystems) but 18S rDNA failed to amplify using Quantitect (Qiagen) on the xxpress, so users 192 
should be aware that rigorous optimisation of different mastermixes is required for fast PCR. To 193 
facilitate development of rapid assays incorporating fast PCR pre-processing steps must be minimised 194 
and there is therefore a growing need to develop enzymes resistant to contaminants and inhibitors 195 
present in a range of biological sample materials, such as soil, water and blood (30)). 196 
Although many prototype rapid PCR systems have been reported with extremely fast ramp rates and 197 
miniaturisation (5), (6), (31)) very few proceed to commercial release. Therefore the xxpress rapid 198 
thermal cycler, particularly given its standard block-based design, offers a unique opportunity for the 199 
wider molecular research community to adopt fast PCR. The potential applications of fast PCR in 200 
situations which require a rapid diagnosis (e.g. involvement of cardiac disease in dyspnoea (32)) or 201 
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chest pain) make this an exciting and rapidly expanding area of PCR development. If protocols can be 202 
developed to enable reverse transcription and PCR directly from patient samples (30)), this platform 203 
has the potential to make point-of care diagnostics based upon circulating microRNAs a reality.  204 
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Tables 358 
Table 1. Oligonucleotides. 359 
 360 
 Name Sequence (5'-3') TM (oC) 
RT oligos miR-21 UAG CUU AUC AGA CUG AUG UUG AAA AAA AAA 
AAA A 
52.4 
OligodT-RACE GCG AGC ACA GAA TTA ATA CGA CTC ACT ATA 
GGT TTT TTT TTT TTV N 
61.9 
Reverse RACE GCG AGC ACA GAA TTA ATA CGA C 53.9 
18 S  18 S Forward AAA CGG CTA CCA CAT CCA AG 55.3 
18 S Reverse CCT CCA ATG GAT CCT CGT TA 53.8 
miRNAs miR-10b-5p TAC CCT GTA GAA CCG AAT TTG TG 54.7 
miR-468-5p TCC TGT ACT GAG CTG CCC CGA 62.8 
miR-126-5p CAT TAT TAC TTT TGG TAC GCG 49.6 
miR-22-3p AAG CTG CCA GTT GAA GAA CTG T 57.1 
miR-21-5p TAG CTT ATC AGA CTG ATG TTG A 50.9 
Y-RNAs Y-RNA-3p CCC CCA CTG CTA AAT TTG ACT 55.2 
Y-RNA-5P GGC TGG TCC GAT GGT AGT 56.8 
Sequence and melting temperatures for oligonucleotides used in this investigation. Column 1 denotes the 
general class of oligonucleotides used and Column 2 the name of each, also providing information about 
target strand (5p or 3p for miRNAs). Column 3 provides sequence information (V denotes any nucleotide 
not T or U and N denotes any nucleotide). Column 4 TM values were calculated by Integrated DNA 
Technologies. 
 361 
 362 
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Table 2. PCR cycling conditions.  363 
 xxpress LightCycler480 
 Temp 
(oC) 
Hold 
(s) 
Ramp rate 
(oC/s) 
Temp 
(oC) 
Hold 
(s) 
Ramp rate 
(oC/s) 
Initial Denaturation 95 20 10 (4.8†)  95 20 4.8 
Denaturation 95 1 10 (4.8†) 95 1 4.8 
Annealing 
Extension* 
60 10 10 (2.5†) 60 10 2.5               
Cooling 50 10 10 (2.5†) 50 10 2.5 
Cycling conditions for PCR. Ramp rates are shown for fast PCR and conventional 
PCR in parentheses. * Fluorescence was measured following each annealing and 
extension step. †Ramp rate used to assess consistency across the plate by amplification 
of 18S rDNA. 
 364 
 365 
 366 
 367 
 368 
 369 
 370 
 371 
 372 
 373 
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Figure legends 374 
Figure 1. The xxpress system. A) 96 well xxplate (bottom) compared to conventional 96 well and 375 
384 well PCR plates (upper). (Scale bar represents 25 cm to allow a direct size comparison). B) The 376 
xxpress system comprises a heat sealer (left), centrifuge (center) and cycler unit (right). 377 
Figure 2. Variability in Ct values across plates on both systems. A single 18S rDNA PCR 378 
mastermix was distributed across 48 wells of both a Lightcycler 384 well plate and xxpress 96 well 379 
xxplate (5 µl reaction/well). PCR was performed with the same ramp rate on each thermal cycler (4.8 380 
°C/s).  Ct values are presented by row from well A1 (active wells are illustrated in Supplementary 381 
Figure.1). Melt curve analysis was performed to confirm amplification of a single product (data not 382 
shown). 383 
Figure 3. Standard curves generated by amplification of 18S rDNA from genomic DNA and 384 
synthetic miR-21. A) 18S rDNA standard curve analysis. Comparable dynamic range 0.1 pg- 10 ng 385 
genomic DNA. Amplified using maximal ramp rate on each platform (n=3 technical replicates) (* p 386 
<0.05, ** p<0.01). B) Synthetic miR-21 standard curve analysis. Comparable dynamic range 109 - 106 387 
copies of template RNA. Amplified using maximal ramp rate on each platform (n=3 technical 388 
replicates). For both datasets melt curve analysis confirmed the presence of a single product (data not 389 
shown). 390 
Figure 4. Detection of microRNAs from human plasma samples by fast and standard PCR analysis. 391 
Cts for 4 microRNAs (miR-21, miR-22, miR-126, miR-486) and Y-RNA (Y-RNA-3p) on plasma 392 
samples from 3 individuals (n=3 technical replicates). The relative levels of expression detected by 393 
both systems were comparable. Gel and melt curve analysis was carried out to confirm amplification 394 
of one product (data not shown). 395 
Supplementary Figure 1. Plate layout. Reported data is presented by row starting from well A1. 396 
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